BioLineRx Ltd.
Pembelian
Diupdate

BLRX-BREAKOUT-UPDATE

389
BLRX had a strong rally today and it's just getting started.

In the related idea my price target was $1.34.

Today's high was $1.78

Check out the weekly chart:

cuplikan

Photo Finish.

$1.34 was 1.618 extension level from Waves 1 & 2.

Since the price-action broke $1.34 we will have an extended 3rd wave.

I expect a very strong rally tomorrow, I will update in the morning before the open to confirm.

Target is hard to predict since its impossible to know what level extending waves will terminate.

I will keep a close eye on the price-action.

Will update.

-AB






Catatan
As expected, a very strong rally today!
Catatan
cuplikan
Catatan
We got a big runway...
Catatan
Reminder this is a WEEKLY chart...

Meaning this move is far from over...
Catatan
cuplikan
Catatan
Buckle up!
Catatan
cuplikan
Catatan
Target $2.24 (Sell Half)

Trade Price: 1.049
Catatan
cuplikan
Catatan
cuplikan
Catatan
Bull Flag
Catatan
BLRX will rally again tomorrow.
Catatan
cuplikan
Catatan
BLRX is about to rally again...
Catatan
BLRX continued to consolidate today.

Staying the course...
Catatan
cuplikan
Catatan
cuplikan
Catatan
Near-Term Target: $2.13
Catatan
cuplikan
Catatan
Primary Wave 1 Complete
Catatan
cuplikan
Catatan
03:21 PM EDT, 10/22/2018 (MT Newswires) -- Oppenheimer has kept its outperform rating on BioLineRx (BLRX) with a price target of $3, betting on BL-8040's commercial opportunity as a stem cell mobilizer after top-line data from the COMBAT/KEYNOTE-202 trial of BL-8040 in combination with pembrolizumab in advanced pancreatic cancer showed modest response rate.
"Given the combination's favorable safety profile, BioLineRx and Merck (MRK) are testing a triplet combination including chemotherapy in an effort to increase response rate," analyst Mark Breidenbach said in a note.
"While we believe the triplet combination is worth testing, our valuation of BioLineRx still remains focused on BL-8040's commercial opportunity as a stem cell mobilizer."
Catatan
cuplikan
Catatan
cuplikan
Catatan
Breakout Imminent
Catatan
cuplikan

Pernyataan Penyangkalan

Informasi dan publikasi ini tidak dimaksudkan, dan bukan merupakan, saran atau rekomendasi keuangan, investasi, trading, atau jenis lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Ketentuan Penggunaan.